Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

346
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
346
Hazard Ratio01:12

Hazard Ratio

122
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
122
Cancer Prevention02:59

Cancer Prevention

6.2K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.2K
Cancer Therapies02:49

Cancer Therapies

7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nemolizumab Versus Dupilumab in the Treatment of Prurigo Nodularis: Systematic Literature Review and Network Meta-analysis.

Dermatology and therapy·2026
Same author

Burden of thromboembolism, disease progression, and phlebotomy among polycythemia vera patients in the United States: a systematic literature review.

Expert review of hematology·2026
Same author

Survival benefit of oral systemic monotherapy in previously treated metastatic colorectal cancer: a meta-analysis.

The oncologist·2026
Same author

Pulmonary Function Decline in Alpha-1 Antitrypsin Deficiency: A Systematic Review and Meta-Analysis.

International journal of chronic obstructive pulmonary disease·2026
Same author

A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas.

Oncology and therapy·2026
Same author

Joint modeling of progression-free survival and patient-reported outcomes to evaluate the association between disease progression and symptoms among patients with relapsed/refractory multiple myeloma.

Journal of patient-reported outcomes·2025

Related Experiment Video

Updated: Jul 2, 2025

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

2.3K

Risk of Venous Thromboembolism by Cancer Type: A Network Meta-Analysis.

Marissa B Betts1, Xuejun Liu2,3, Daniela R Junqueira1

  • 1Evidera, Waltham, Massachusetts.

Seminars in Thrombosis and Hemostasis
|February 23, 2024
PubMed
Summary

Cancer patients face a higher risk of venous thromboembolism (VTE). Pancreatic, brain, and ovarian cancers show elevated VTE risk, influenced by stage, chemotherapy, and surgery.

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

267
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.2K

Related Experiment Videos

Last Updated: Jul 2, 2025

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

2.3K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

267
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.2K

Area of Science:

  • Oncology
  • Epidemiology
  • Biostatistics

Background:

  • Patients with cancer exhibit an elevated risk of venous thromboembolism (VTE).
  • Accurately comparing tumor-specific VTE risk is challenging due to confounding factors like surgery, disease stage, and chemotherapy.
  • Network meta-analysis (NMA) offers a robust method to estimate VTE rates across different cancer types while accounting for baseline risks.

Approach:

  • A systematic literature search of Embase, MEDLINE, and Cochrane Library identified clinical trials and observational studies (2005-2022) assessing cancer-related VTE risk.
  • Included studies focused on distinct cancer types with comparable populations and methodologies, reporting VTE within one year of diagnosis.
  • Random-effects Bayesian NMAs were employed to estimate relative VTE rates, anchored by lung cancer incidence for absolute rate calculation.

Key Points:

  • The NMA encompassed 30 studies, analyzing 3,948,752 patients across 18 cancer types.
  • Overall, 3.1% of patients experienced VTE within one year of diagnosis, with cancer-specific rates varying from 0.7% to 7.4%.
  • Pancreatic, brain, and ovarian cancers demonstrated higher-than-average VTE risk, aligning with existing prediction tools.

Conclusions:

  • The study successfully estimated cancer-specific VTE risks using NMA, providing a comparative framework.
  • VTE risk rankings for certain cancers were found to be dynamic, influenced by disease stage, chemotherapy, and surgical interventions.
  • These findings aid in refining VTE risk stratification and management strategies in oncology patients.